Skip to main content
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. — Investor Relations & Filings

Ticker · CTMX ISIN · US23284F1057 LEI · 5493004VW2FW0QLL3345 US Manufacturing
Filings indexed 751 across all filing types
Latest filing 2025-11-10 Director's Dealing
Country US United States of America
Listing US CTMX

About CytomX Therapeutics, Inc.

https://cytomx.com/

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company is developing a novel class of antibody therapeutics based on its proprietary Probody® platform. This technology creates masked, conditionally activated biologics designed to be activated specifically within the tumor microenvironment. The goal of this approach is to localize therapeutic activity to the tumor, thereby creating more potent and less toxic treatments for cancer patients. CytomX is advancing a pipeline of Probody drug candidates through its own research and strategic partnerships to address various cancer types.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-11-10 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-07 English
Regulatory Filings 2025
Regulatory Filings
2025-11-06 English
8-K
Regulatory Filings
2025-11-06 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-06 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.